Research in Clinical Dermatology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Mini Review - Research in Clinical Dermatology (2024) Volume 7, Issue 4

Advancements in Melanoma Treatment: From Surgery to Immunotherapy

Babatunde Ayodele *

Department of Clinical Dermatology, Obafemi Awolowo University, Nigeria

*Corresponding Author:
Babatunde Ayodele
Department of Clinical Dermatology, Obafemi Awolowo University, Nigeria
E-mail: babatunde.ayodele@oauife.edu.ng

Received: 1-July-2024, Manuscript No. aarcd-24- 144716; Editor assigned: 3-July-2024, PreQC No. aarcd-24- 144716 (PQ) Reviewed:17-July-2024, QC No. aarcd-24- 144716 Revised:24-July-2024,Manuscript No. aarcd-24- 144716; Published:30-July -2024,DOI: 10.35841/aarcd- 7.4.218

Citation: Ayodele B. Advancements in melanoma treatment: From surgery to immunotherapy. Res Clin Dermatol. 2024;7(4):218

Visit for more related articles at Research in Clinical Dermatology

Introduction

Melanoma, the most dangerous form of skin cancer, has historically posed significant challenges in the medical community due to its aggressive nature and propensity for metastasis. Over the years, however, advancements in treatment have dramatically improved prognosis and survival rates. This article explores the evolution of melanoma treatment, from traditional surgical methods to the cutting-edge realm of immunotherapy [1].

In the early stages of melanoma treatment, surgery was the cornerstone. The primary goal was to remove the tumor entirely before it could spread to other parts of the body. Excision with clear margins, ensuring no cancer cells were left behind, was critical. In cases where melanoma was caught early, surgical intervention often resulted in a high cure rate. However, once the melanoma had metastasized, surgery alone proved insufficient [2].

As melanoma research progressed, radiation therapy and chemotherapy emerged as adjunct treatments. Radiation therapy, using high-energy rays to target and kill cancer cells, provided a non-invasive option for patients who could not undergo surgery. Meanwhile, chemotherapy, involving drugs that kill rapidly dividing cells, offered a systemic treatment approach. Despite these advances, the survival rates for advanced melanoma remained dismally low, and the side effects of chemotherapy were often debilitating [3].

The discovery of specific genetic mutations in melanoma cells paved the way for targeted therapy. Drugs like vemurafenib and dabrafenib, which inhibit the BRAF mutation found in about half of all melanomas, marked a significant breakthrough. These therapies specifically target cancer cells with the mutation, sparing healthy cells and resulting in fewer side effects compared to traditional chemotherapy. Although targeted therapies significantly improved outcomes, resistance often developed, necessitating the exploration of additional treatment strategies [4].

The most revolutionary advancement in melanoma treatment has been the development of immunotherapy. This approach harnesses the body’s immune system to recognize and attack cancer cells. Checkpoint inhibitors, such as ipilimumab, nivolumab, and pembrolizumab, have shown remarkable success. These drugs work by blocking proteins that inhibit immune response, thereby allowing the immune system to target melanoma cells more effectively [5].

Combining different therapeutic approaches has emerged as a potent strategy against melanoma. For instance, combining checkpoint inhibitors with targeted therapies has demonstrated improved efficacy. Additionally, combining different checkpoint inhibitors, like nivolumab and ipilimumab, has shown superior results in some patients, though with increased risk of side effects. Researchers continue to explore optimal combinations to enhance treatment outcomes and minimize adverse effects [6].

Advances in genetic profiling have enabled personalized medicine, tailoring treatment plans based on the individual’s genetic makeup and specific tumor characteristics. This approach allows for more precise targeting of cancer cells and improves the likelihood of treatment success. Personalized medicine represents a significant leap forward in oncology, offering hope for more effective and less toxic melanoma treatments [7].

Oncolytic virus therapy is an innovative approach where viruses are engineered to infect and kill cancer cells while stimulating an immune response. Talimogene laherparepvec (T-VEC), the first FDA-approved oncolytic virus therapy for melanoma, has shown promise in shrinking tumors and enhancing the effectiveness of other treatments. This emerging field continues to evolve, with ongoing research aimed at optimizing virus-based therapies [8].

Clinical trials have been instrumental in advancing melanoma treatment. These studies not only test the safety and efficacy of new therapies but also provide patients access to cutting-edge treatments that are not yet widely available. Participation in clinical trials has contributed significantly to the rapid development and approval of novel therapies, bringing new hope to melanoma patients worldwide [9].

Despite the advancements, treatment resistance remains a significant challenge in melanoma therapy. Cancer cells can adapt and develop resistance to both targeted therapies and immunotherapies. Understanding the mechanisms behind this resistance is crucial for developing new strategies to overcome it. Ongoing research focuses on identifying biomarkers that predict resistance and developing next-generation therapies to address this issue [10].

Conclusion

The journey from traditional surgery to advanced immunotherapy has revolutionized melanoma treatment, significantly improving patient outcomes. While challenges such as treatment resistance persist, the relentless pursuit of innovative therapies and personalized medicine continues to push the boundaries of what is possible. With ongoing research and clinical trials, the future looks promising for melanoma patients, offering hope for longer, healthier lives.

References

  1. Shajari N, Baradaran B, Tohidkia MR, et al. Advancements in Melanoma Therapies: From Surgery to Immunotherapy. Curr Treat Options Oncol. 2024:1-6.

    2. Indexed at, Google Scholar, Cross Ref

  2. Trojaniello C, Luke JJ, Ascierto PA. Therapeutic advancements across clinical stages in melanoma, with a focus on targeted immunotherapy. Front oncol. 2021;11:670726.

    3. Indexed at, Google Scholar, Cross Ref

  3. Franklin C, Livingstone E, Roesch A, et al. Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol. 2017;43(3):604-11.

    4. Indexed at, Google Scholar, Cross Ref

  4. Naik PP. Current trends of immunotherapy in the treatment of cutaneous melanoma: A review. Dermatol Ther. 2021;11(5):1481-96.

    5. Indexed at, Google Scholar, Cross Ref

  5. Mooradian MJ, Sullivan RJ. Immunotherapy in melanoma: Recent advancements and future directions. Cancers. 2023;15(16):4176.

    6. Indexed at, Google Scholar, Cross Ref

  6. Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: Recent advances and future directions. Cancers. 2023;15(4):1106.

    7. Indexed at, Google Scholar, Cross Ref

  7. Sood S, Jayachandiran R, Pandey S. Current advancements and novel strategies in the treatment of metastatic melanoma. Integr Cancer Ther. 2021;20:1534735421990078.

    8. Indexed at, Google Scholar, Cross Ref

  8. Saranga?Perry V, Ambe C, Zager JS, et al. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin. 2014;64(3):171-85.

    9. Indexed at, Google Scholar, Cross Ref

  9. Rodríguez-Cerdeira C, Carnero Gregorio M, López-Barcenas A, et al. Advances in immunotherapy for melanoma: A comprehensive review. Mediators Inflamm. 2017;2017(1):3264217.

    10. Indexed at, Google Scholar, Cross Ref

  10. Kuryk L, Bertinato L, Staniszewska M, et al. From conventional therapies to immunotherapy: Melanoma treatment in review. Cancers. 2020;12(10):3057.

    11. Indexed at, Google Scholar, Cross Ref

Get the App